<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595281</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01511-46</org_study_id>
    <nct_id>NCT02595281</nct_id>
  </id_info>
  <brief_title>HE4 as a Relapse Biomarker in Ovarian Cancers</brief_title>
  <acronym>PRONOV4IR</acronym>
  <official_title>Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of
      serum HE4 before surgery has been demonstrated to predict overall survival and its interest
      has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk
      patients. To date, no study shows clearly the predictive potential of serum HE4 as an early
      relapse biomarker in ovarian cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the predictive and prognostic value of HE4 marker</measure>
    <time_frame>24 months</time_frame>
    <description>Serum concentration of HE4 (pMol) will be analysed at each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the evolution of HE4 and CA-125 serum concentration</measure>
    <time_frame>24 months</time_frame>
    <description>Serum concentration of HE4 and CA-125 (pMol) will be analysed and compared at the time of diagnosis, at each neoadjuvant chemotherapy cycle, before the surgery, and at each chemotherapy cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival at 18 months</measure>
    <time_frame>24 months</time_frame>
    <description>HE4 and CA125 will be compared with the rate of progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of surgery</measure>
    <time_frame>24 months</time_frame>
    <description>HE4 and CA125 will be compared with completeness of cancer resection score (CCR score).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Serum samples are collected:
at each neoadjuvant chemotherapy cycle
before surgery
at each adjuvant chemotherapy cycle
at each injection of bevacizumab as maintenance therapy
stop at the progression or after 24 months post chemotherapy</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ovarian adenocarcinoma stage IIIa, IIIb or IV pleural, cytologically or histologically
             proven

          -  Patient scheduled to undergo neoadjuvant chemotherapy based on platinum followed by
             surgery and adjuvant chemotherapy

          -  Age ≥ 18 years .

          -  Performance status ECOG &gt; or = 2

          -  Adequate haemoglobin rate ≥ 10 g/dL

          -  Ability to provide written informed consent

          -  Patient's legal capacity to consent to study participation

        Exclusion Criteria:

          -  Any previous treatment with platinum for ovarian carcinoma

          -  Patient with visceral metastases

          -  Contraindication for blood test

          -  Contraindication for surgery

          -  Contraindication for bevacizumab treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline Gavoille, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis Merlin, Pr</last_name>
    <phone>+ 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurinda Fernandes</last_name>
    <phone>+ 33 3 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BENGRINE-LEVEVRE Leïla</name>
      <address>
        <city>Dijon</city>
        <state>Centre Georges François Leclerc</state>
        <zip>21 079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENGRINE-LEVEVRE Leïla, Dr</last_name>
      <phone>+00 33 3 80 73 77 74</phone>
      <email>lbengrine@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZEMAR Marc</name>
      <address>
        <city>Strasbourg</city>
        <state>Centre Paul Strauss</state>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AZEMAR Marc, Md</last_name>
      <email>mazemar@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LONGO Raphaelle</name>
      <address>
        <city>Metz</city>
        <state>CHU Metz Thionville</state>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LONGO Raphaelle, MD</last_name>
      <email>r.longo@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KURTZ Jean-Emmanuel</name>
      <address>
        <city>Strasbourg</city>
        <state>Hôpital Civil</state>
        <zip>67 091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KURTZ Jean-Emmanuel, Pr</last_name>
      <phone>+ 33 3 88 11 67 28</phone>
      <email>j-emmanuel.kurtz@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KALBACHER Elsa</name>
      <address>
        <city>Besançon</city>
        <state>Hôpital Jean Minjoz</state>
        <zip>25 030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KALBACHER Elsa, Dr</last_name>
      <phone>+33 3 81 66 83 11</phone>
      <email>ekalbacher@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GAVOILLE Céline</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Institut De Cancérologie De Lorraine</state>
        <zip>54 519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavoille Céline, Dr</last_name>
      <phone>+33 3 83 59 83 31</phone>
      <email>c.gavoille@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAVOYE Aude-Marie</name>
      <address>
        <city>Reims</city>
        <state>Institut Jean Godinot</state>
        <zip>51 056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAVOYE Aude-Marie, Dr</last_name>
      <phone>+33 3 26 50 43 84</phone>
      <email>aude-marie.savoye@reims.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.he4test.com/row/professionals/about_he4.html</url>
    <description>Fujirebio Diagnostics,Inc</description>
  </link>
  <reference>
    <citation>Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec;13(4):179-87. Review.</citation>
    <PMID>10228898</PMID>
  </reference>
  <reference>
    <citation>Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013 Apr;66(4):273-81. doi: 10.1136/jclinpath-2012-201031. Epub 2013 Feb 20. Review.</citation>
    <PMID>23426716</PMID>
  </reference>
  <reference>
    <citation>Kalapotharakos G, Asciutto C, Henic E, Casslén B, Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012 Aug 21;5(1):20. doi: 10.1186/1757-2215-5-20.</citation>
    <PMID>22909379</PMID>
  </reference>
  <results_reference>
    <citation>Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023. Epub 2012 Nov 21.</citation>
    <PMID>23178313</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Carcinoma</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>ROMA</keyword>
  <keyword>Ca125</keyword>
  <keyword>HE4</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

